ESMO 2019: Kisqali shows superior overall survival in breast cancer - 1 views
-
jacob logan on 07 Oct 19Novartis has said that Kisqali delivered superior overall survival (OS) in the Monaleesa-3 trial, demonstrating more life for postmenopausal human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer patients.